SPONSORSHIP ALLIANCE NEWS
Innovative Rural Treatment Center in Paraguay Showcases State-of-the-Art Non-Invasive Brain Tumor Therapy
Read the latest article from Dr. Raj Singh et al. from The Ohio State University Comprehensive Cancer Center. The authors report on local control (LC), toxicity, and overall survival (OS) following stereotactic ablative radiation therapy (SABR) for extracranial metastases from malignant melanoma.
Read the latest article in MReadings by Joshua Kim et al from Henry Ford Health Department of Radiation Oncology. Dr. Kim's work demonstrates the 0.55T MAGNETOM Free.Max RT Edition, when used with an optimized imaging protocol that includes 3D T1 FLASH and 3D T2 FLAIR SPACE sequences, provides image quality sufficient for target and OAR delineation in stereotactic radiotherapy planning. Total protocol times are clinically acceptable, demonstrating that this low-field MR system is a viable and valuable option for MR simulation in radiotherapy.
Watch the latest Spilling the RT episode with Dr. Arjun Sahgal, a world-renowned radiation oncologist. In this episode, Dr. Sahgal shares inspiring progress around the initial results of the UNITED (Unity-Based MR-Linac Guided Adaptive Radiotherapy for High Grade Glioma) trial. UNITED is the world’s first adaptive MR-guided radiotherapy study for patients with high-grade gliomas, the most common and aggressive primary brain tumors found in adults, and the highlight of his illustrious career so far. Listen here: Breakthrough in high-grade glioma cancer treatment | Dr. Arjun Sahgal on Spilling the RT - YouTube
We’ve just launched a new online resource created specifically for patients and families navigating treatment for brain cancer and other cranial conditions.Learn more about ZAP-X® Gyroscopic Radiosurgery® and what to expect—presented in a simple, supportive way to guide patients through every step of the journey.
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).
In LAURA Phase III trial, Tagrisso continues to demonstrate improved overall survival trend in unresectable, Stage III setting
SAVANNAH and ORCHARD Phase II trials show the addition of Orpathys or Datroway to Tagrisso upon disease progression demonstrates strong clinical activity
Deadline for article submission is extended to May 20!
In collaboration with the Cureus Journal of Medical Science (Springer Nature), ZAP is proud to sponsor the Dedicated Cranial Radiosurgery: Clinical Experience with New & Innovative SRS Technologies publishing competition. Looking at novel SRS-exclusive delivery platforms, the program seeks case reports, case series and/or technical reports. All resulting publications will be indexed with Pub-Med Central.
It's a great opportunity to showcase your expertise in state-of-the-art radiosurgery, and educate your peers on new and innovative technologies. And there are $9,000 USD in honoraria to be awarded via crowd-sourced scoring across the top 3 article authors.
For more details, please visit https://www.cureus.com/competitions/CranialSRS
The deadline for abstract submissions for the Leksell Gamma Knife Society meeting is fast approaching, with the final call closing on June 30, 2025. Don't miss this opportunity to share your research and contribute to the collective knowledge of the community. Submit your abstracts at the following link.
The meeting, themed "Continue to Lead", will bring together radiosurgery experts from around the world to discuss the latest advancements and innovations in Gamma Knife technology on October 19-21, 2025 in Stockholm.
For more information on submission guidelines and to submit your abstract, please visit the Leksell Gamma Knife Society's official website.
In collaboration with the Cureus Journal of Medicine (Springer Nature), ZAP is proud to sponsor the Dedicated Cranial Radiosurgery: Clinical Experience with New & Innovative SRS Technologies publishing competition. Looking at novel SRS-exclusive delivery platforms, the program seeks case reports, case series and/or technical reports. All resulting publications will be indexed with Pub-Med Central.
$9,000 USD in honoraria awarded via crowd-sourced scoring across the top 3 article authors.
Deadline for draft article submission is April 22, 2025. For more details, please visit https://www.cureus.com/competitions/CranialSRS.
The next-generation Radiosurgery Planning System (RPS) specifically engineered to harness the full potential of the ZAP-X® Gyroscopic Radiosurgery® platform*. Axon delivers unmatched simplicity, remarkable speed, and clinical excellence, setting a new benchmark in cranial SRS treatment planning.
* Pending USA FDA and EU CE clearance
Learn more about the new ZAP-Axon Radiosurgery Planning System here.
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.